drugset / Trial / NCT01914744
Entecavir Versus Lamivudine for Preventing the Risk of Hepatitis B Reactivation in NHL
RandomizedParallel-groupOpen-labelPrevention
Summary
The aim of this study is to prove the superiority of entecavir over lamivudine for preventing the risk of hepatitis B virus reactivation in patients with non-Hodgkin lymphoma on CHOP/R-CHOP.
Timeline
- Start
- 2013-02
- Primary completion
- 2015-12
- Completion
- 2016-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Entecavir | Small molecule | 0.5 mg | Oral |
| Subject | Lamivudine | Other / unclassified | 100 mg | Oral |